Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease
source: Clinical Infectious Diseases
year: 2017
authors: Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M
summary/abstract:Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed dose combination, ledipasvir and sofosbuvir for 12 weeks in this population.
organization: Johns Hopkins University School of Medicine, Baltimore; Gilead Sciences, Inc., Foster City USADOI: 10.1093/cid/cix441
read more full text
+myBinderRelated Content
-
Use of Marijuana in Patients with Sickle Cell Disease Increased the Frequency of Hospitalization for Acute Painful V...Introduction: Recently, there has been g...
-
Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complicat...Background: Exercise could be a trigger...
-
Infographic: Understanding Sickle Cell Disease – ASHhttps://www.onescdvoice.com/wp-content/u...
-
Family Celebrates 7-Year-Old’s Sickle Cell Cure Thanks to Sister’s Life-Saving GiftOne 7-year-old who suffered his whole li...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
-
Gene therapy may help cure sickle cell disease, study saysA gene therapy that could provide a perm...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.